Regenerative Therapy

A dendritic cell vaccine personalized for each individual based on the patient’s own tumor was reported to increase median survival time in  glioblastoma patients. An early phase study at UCLA’s Jonsson Comprehensive Cancer Center.
The study found that the vaccine, administered after the conventional treatments of surgery and radio-chemotherapy, was associated with a median survival of 31.4 months, double the 15 months of historical controls in the published literature. 23 patients were enrolled in the Phase I …

Multikine® is a patented defined mixture of biologically active, natural cytokines that simulate the body’s healthy immune response. The cytokine mixture includes interleukins, interferons, chemokines, and colony-stimulating factors.
Planned Study Summary: A Pivotal Phase III, Open-label, Randomized, Multi-center Global Study of the Effects of Multikine Plus Standard of Care (Surgery + Radiotherapy or Surgery + Concurrent Chemoradiotherapy) in Subjects with Advanced Primary Squamous Cell Carcinoma of the Oral Cavity Versus Standard of Care Only. The goal …

ICT-107 is an autologous personalized, dendritic cell-based vaccine that works by activating a patient’s immune system against specific tumor-associated antigens. Extracting dendritic cells from a patient, loading them with the antigens, and reintroducing them to the patient’s body to trigger an immune response.
Developed by Immunocelular Therapeutics Lt. California, US.
http://www.imuc.com/
The company  has finished a Phase I trial of ICT-107 in patients with glioblastoma multiforme (GBM), the most common and most aggressive type of primary brain tumor. A …

Clinical study for treatment of breast cancer, combining chemotherapy, stem cell transplant and adoptive immunotherapy with activated lymphocytes for treating women with stage IV breast cancer.
The chemotherapy treatment is followed by peripheral blood stem cell transplantation plus autologous and ex vivo expanded T lymphocytes.
Phase II pilot clinical study in two medical centers in the US, October 2010 recruiting patients

Barbara Ann Karmanos Cancer Institute
 

Detroit, Michigan, United States

Sinai-Grace Hospital
 

Detroit, Michigan, United States

Clinical study website  http://clinicaltrials.gov/ct2/show/NCT00020722?term=Lawrence+Lum&rank=1

A Pilot Study to Assess the Safety and Feasibility of Autologous Tumor Cell-TLR9 Agonist Vaccination Prior to Autologous Hematopoietic and Immune Cell Rescue in Metastatic Colorectal Cancer.

Phase I clinical study for the treatment of 10 patients with metastatic colorectal cancer. Resected tumor cells will be irradiated and mixed with CpG to create a vaccine. Patients will receive subcutaneous vaccination at weeks 1 and 2 after resection. Six weeks later, immune T cells and then G-CSF …

Clinical study of active immunization into the urine bladder with macrophages derived from the patient’s blood.
Phase II/III, multicentre, open-label, randomised study comparing autologous intravesical macrophage cell therapy (Bexidem®) to intravesical Bacillus Calmette-Guerin (BCG) therapy in patients with superficial papillary bladder cancer who have undergone complete transurethral resection.
http://www.controlled-trials.com/ISRCTN35881130/ISRCTN35881130
Study sponsored by Millennium: The Takeda Oncology Company ( IDM Pharma SA), France.
http://www.millennium.com/science/idm_transitional.asp

Clinical trial results of Bristol-Myers Squibb Company’s ipilimumab for mleanoma. The results, reported by Dr. Steven O’Day at the 2010 Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago and published June 5th in the New England Journal of Medicine, indicate that ipilimumab significantly improved the survival of patients with late stage melanoma, either as the only cancer-fighting agent, or in combination with a cancer vaccine.
Ipilimumab is a human monoclonal antibody that …

Phase 3 Clinical Trial: The study will enroll approximately 700 previously untreated patients with Stage I or II surgically-resected cancer of the pancreas who have no visible disease detectable by a CT scan. Patients will be randomly assigned to receive the current standard of care, either Gemcitabine alone or Gemcitabine +5-FU and radiation with or without HyperAcute-Pancreas immunotherapy at about 50 major medical centers.
HyperAcute products are composed of irradiated, allogeneic (off the shelf), whole cancer …

ImmunoCellular Therapeutics recently completed a Phase I trial of its lead product candidate, ICT-107, a dendritic cell-based vaccine targeting multiple tumor associated antigens for glioblastoma. The Company is planning to initiate a multicenter phase II study in the second half of 2010.
Surasak Phuphanich, M.D., Director of the neuro-oncology program at the Cedars-Sinai Medical Center and the study’s lead investigator, will present the poster titled, “Immune response correlation with progression-free survival in glioblastoma following dendritic cell …

GlaxoSmithKline individualized vaccine.  The trial will seek to determine if the treatment delays the recurrence of cancer in patients with non-small cell lung cancer after they have had surgery to remove their tumors.  Double-blinded randomized trial. About 30% of such patients will be positive for the relevant antigen and thus will be eligible for treatment.  400 centers in 33 countries participating in the study.
Upstate Medical University, Syracuse, NY, US
http://www.syracuse.com/news/index.ssf/2010/05/local_people_with_non-small_ce.html